By Sneha S K (Reuters) -Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh ...

Tariffs and federal research “uncertainty” are forcing a Peninsula company to lay off workers at headquarters and cut other ...

Bernstein analyst Eve Burstein lowered the firm’s price target on PacBio (PACB) to $1.50 from $2 and keeps an Outperform rating on the shares.

Shares of PacBio (PACB) traded nearly 20% higher on Wednesday after the company said it is executing a plan, including job ...

A major new initiative was launched on Tuesday (15 April) by the Wellcome Sanger Institute in collaboration with Pacific ...

Rady study uses PacBio long-read sequencing for RFX3 variant in adolescent patient with autism, showcasing clinical genomics ...

PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...

Tariffs and federal research “uncertainty” are forcing this Menlo Park biotech company to lay off workers at headquarters and ...

Shares of Pacific Biosciences of California climbed after the company backed its prior outlook and announced cuts to its spending and workforce. The stock rose 9.6% to $1.32 in mid-morning trading.

US sequencing firm PacBio (Nasdaq: PACB) is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal ...

In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a ...